At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 132 enrolled
Drug / intervention
ME3183 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Efficacy and Safety of ME3183 Administered Orally in Subjects With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating ME3183 and Placebo for Plaque Psoriasis. Completed, enrolled 132 participants across 27 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of ME3183 administered orally for moderate to severe plaque psoriasis in adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartMar 2022
Primary CompletionMay 2023
TodayJul 2026
First PostedMar 7, 2022
Enrollment StartMar 24, 2022
Primary CompletionMay 31, 2023
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.3 years ago
Interventions
ME3183drug
ME3183 capsule
Placebodrug
Placebo capsule